Vertex Pharmaceuticals's revenue for the
three
months ended in Jun. 2022 was $2,196 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $8,350 Mil.
Vertex Pharmaceuticals's Revenue per Share for the
three
months ended in Jun. 2022 was $8.49.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $32.33.
During the past 12 months, the average Revenue per Share Growth Rate of Vertex Pharmaceuticals was 26.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 35.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 33.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 19.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Vertex Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 129.40% per year. The lowest was -32.50% per year. And the median was 25.80% per year.
Vertex Pharmaceuticals Revenue Historical Data
The historical data trend for Vertex Pharmaceuticals's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Revenue
2,488.65
3,047.60
4,162.80
6,205.70
7,574.40
Vertex Pharmaceuticals Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Revenue
1,793.40
1,984.16
2,072.56
2,097.50
2,196.20
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Revenue Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Revenue falls into.
Vertex Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,350 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Vertex Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.53(0.83%) Volume: 1,103,648 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VRTX has been successfully added to your 
